Roche's Kadcyla reduces the risk of breast cancer recurrence after surgery

, Roche's Kadcyla significantly outperformed Herceptin in reducing the risk of breast cancer recurrence in patients with residual disease after surgery, according to new findings presented at the San Antonio Breast Cancer Symposium.data from the Phase III KATHERINE study show that Kadcyla as a single drug significantly reduced the risk of recurrence or death by 50 percent after the new complementary treatment of early breast cancer (eBC) compared to Herceptin as an auxiliary (post-surgery) treatment of HER2-positive patients., 88.3 percent of patients treated with Kadcyla did not have breast cancer, compared with 77.0 percent of those treated with Herceptin, an improvement of 11.3 percent."KATHERINE results show a significant reduction in the risk of HER2-positive early breast cancer recurrence in patients with new complementary treatments, and we look forward to submitting these data to the health sector as soon as possible," said Sandra Horning, Roche's chief medical officer and head of global product development.Kadcyla is an antibody-drug coupled (ADC) that provides effective chemotherapy directly to HER2-positive cancer cells and may limit damage to healthy tissue.the drug is the only single drug approved for treatment of HER2-positive metastasis breast cancer patients who have previously received chemotherapy for Hercetin and yew alkane individually or in combination.the results of the KATHERINE trial will pave the way for drug use in early-stage breast cancer treatment pathways. (This net special article)